 |
|
|
| |
Long-Term Tolerability of Elvitegravir/cobicistat/emtricitabine/tenofovir DF Compared to
Efavirenz/emtricitabine/tenofovir DF or Ritonavir-Boosted Atazanavir Plus Emtricitabine/tenofovir DF in Treatment-Naive HIV-1-Infected Subjects
|
| |
| |
Reported by Jules Levin
53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 10-13, 2013Denver, CO, USA
P Shalit1, J Gallant2, A Mills3, G Crofoot4, T Nguyen5, H Liu5, M Rhee5, J Szwarcberg5
1Peter Shalit, MD, Seattle, WA; 2Southwest CARE Center, Santa Fe, New Mexico; 3Anthony Mills, MD, Inc., Los Angeles, CA;
4Gordon Crofoot, MD, Inc., Houston, TX; 5Gilead Sciences, Inc., Foster City, CA
|
| |
|
|
|
|
|
